Case Discussion Forum
A 62-year-old market trader from Ile-Ife presents with severe solid-food dysphagia. He lost 14 kilograms over four months. Local clinics managed him on empirical proton pump inhibitors for presumed peptic ulcer disease. He only sought specialist care when he could no longer keep water down.
Endoscopy reveals a bulky, ulcerated mass spanning the squamocolumnar junction. The tumor extends 2 cm into the distal esophagus and 3 cm into the gastric cardia. This is a classic Siewert Type II lesion. Biopsy confirms moderately differentiated adenocarcinoma.
CT chest, abdomen, and pelvis show cT3N1M0 disease. The local lymph nodes are enlarged. There is no evidence of distant metastasis.
The surgical oncology team wants to operate immediately to relieve the obstruction. Medical oncology insists on neoadjuvant therapy. The patient is funding his care entirely out-of-pocket.
You ordered for immunohistochemistry for HER2, mismatch repair proteins, and PD-L1 Combined Positive Score at an outside private laboratory. The results will take at least three weeks to return.
Discussion Prompts for the Fellows
1. Defend your choice between perioperative FLOT and preoperative CROSS chemoradiation for this specific Siewert II tumor.
2. Address the baseline neuropathy. Explain how you will adjust the oxaliplatin component of your systemic therapy plan.
3. Establish a protocol for the structured monitoring of treatment-induced adverse events for this patient. Specify how you will track subjective toxicity markers between his clinic visits.
4. Formulate a clinical strategy for the three-week waiting period. Argue whether it is safe to initiate systemic therapy before the full biomarker profile returns.
Note: Attempt at least three of the questions and respond to at least one of your colleagues' comments.
| Status | Discussion | Started by | Last post | Replies | Actions |
|---|---|---|---|---|---|
|
Locked
|
|
|
0 |
|
|
|
|
|
1 |
|
||
|
|
|
1 |
|